Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

Michael L. Wang · SciRah

Researcher profile · Semantic Scholar

Michael L. Wang

Share profile

Michael L. Wang — researcher profile on SciRah

h-index: 74
Works: 587
Citations: 27K

Most-cited papers

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
J. Abramson, M. Palomba, Leo I. Gordon, M. Lunning +18 more
2020The Lancet2,039 citations
Semantic Scholar
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang, J. Muñoz, A. Goy, F. Locke +21 more
2020New England Journal of Medicine1,449 citations Open access
Semantic Scholar
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
A. Mato, N. Shah, W. Jurczak, Che-Ah Y. Chan +40 more
2021The Lancet374 citations Open access
Semantic Scholar
Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma
P. Strati, Saira S. Ahmed, F. Furqan, L. Fayad +26 more
2021Blood196 citations Open access
Semantic Scholar
CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity.
U. Greenbaum, P. Strati, R. Saliba, J. Torres +27 more
2021Blood Advances144 citations Open access
Semantic Scholar
Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis.
H. Hill, Xinyue Qi, P. Jain, K. Nomie +3 more
2020Blood Advances101 citations Open access
Semantic Scholar
Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma.
P. Strati, L. Nastoupil, J. Westin, L. Fayad +27 more
2020Blood Advances99 citations Open access
Semantic Scholar
Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma.
C. Tam, Stephen Samuel Opat, D. Simpson, G. Cull +10 more
2021Blood Advances95 citations Open access
Semantic Scholar
TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma
V. Jiang, Da-Peng Hao, P. Jain, Yi-Jing Li +16 more
2022Molecular Cancer71 citations Open access
Semantic Scholar
Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma
P. Jain, Shuang-Tao Zhao, Hun Lee, H. Hill +23 more
2021Journal of Clinical Oncology59 citations Open access
Semantic Scholar
Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma
Shao-Jun Zhang, V. Jiang, Guang-Chun Han, Da-Peng Hao +34 more
2021Nature Communications56 citations Open access
Semantic Scholar
Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL)
J. Abramson, M. Palomba, L. Gordon, M. Lunning +13 more
2021Blood52 citations Open access
Semantic Scholar
Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma
R. Steiner, J. Banchs, E. Koutroumpakis, M. Becnel +16 more
2021Haematologica48 citations Open access
Semantic Scholar
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies
R. Furman, J. Byrd, R. Owen, S. O'Brien +19 more
2021Leukemia48 citations Open access
Semantic Scholar
Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study
Michael L. Wang, R. Ramchandren, Robert W. Chen, Lionel Karlin +11 more
2021Journal of Hematology & Oncology46 citations Open access
Semantic Scholar
Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis
Shi-Jia Zhang, A. Kulkarni, Beibei Xu, H. Chu +5 more
2020Blood Cancer Journal40 citations Open access
Semantic Scholar
Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials
K. Zhou, D. Zou, Jian-Feng Zhou, Jian-Da Hu +18 more
2021Journal of Hematology & Oncology33 citations Open access
Semantic Scholar
ASTCT, CIBMTR and EBMT Clinical Practice recommendations for transplant and cellular therapies in mantle cell lymphoma.
P. Munshi, M. Hamadani, Ambuj Kumar, P. Dreger +30 more
2021Bone Marrow Transplantation30 citations Open access
Semantic Scholar
Advances in the assessment of minimal residual disease in mantle cell lymphoma
Dayoung Jung, P. Jain, Yi-Xin Yao, Michael L. Wang
2020Journal of Hematology & Oncology28 citations Open access
Semantic Scholar
Haemophagocytic lymphohistiocytosis (HLH) in patients with large B-cell lymphoma treated with standard of care (SOC) axicabtagene ciloleucel (Axi-cel).
Saira S. Ahmed, F. Furqan, P. Strati, J. Westin +16 more
2020Journal of Clinical Oncology25 citations
Semantic Scholar
Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations
Y. Che, Yang Liu, Yi-Xin Yao, H. Hill +7 more
2023Blood Cancer Journal24 citations Open access
Semantic Scholar
Phase 1/2 study of cirmtuzumab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL).
Hun Lee, M. Choi, T. Siddiqi, J. Barrientos +14 more
202123 citations
Semantic Scholar
BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma—Finding a Dancing Partner
J. Muñoz, Yucai Wang, P. Jain, Michael L. Wang
2022Current Oncology Reports21 citations Open access
Semantic Scholar
VLS-101, a ROR1-Targeting Antibody-Drug Conjugate, Demonstrates a Predictable Safety Profile and Clinical Efficacy in Patients with Heavily Pretreated Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma
Michael L. Wang, J. Barrientos, R. Furman, M. Mei +16 more
202017 citations Open access
Semantic Scholar
Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib
P. Jain, R. Kanagal-Shamanna, Shao-Jun Zhang, Young-Ok Chi +13 more
2021American journal of hematology/oncology16 citations Open access
Semantic Scholar
Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials
Yucai Wang, Shou-Hao Zhou, Xinyue Qi, Fang Yang +5 more
2022Blood Cancer Journal15 citations Open access
Semantic Scholar
American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma
P. Munshi, M. Hamadani, Ambuj Kumar, P. Dreger +30 more
2021Transplantation and Cellular Therapy15 citations Open access
Semantic Scholar
EZH2 expression is associated with inferior overall survival in mantle cell lymphoma
D. Martínez-Baquero, A. Sakhdari, H. Mo, D. Kim +12 more
2021Modern Pathology14 citations Open access
Semantic Scholar
Prognostic impact of dose, duration, and timing of corticosteroid therapy in patients with large B-cell lymphoma treated with standard of care axicabtagene ciloleucel (Axi-cel).
P. Strati, F. Furqan, J. Westin, L. Fayad +16 more
202014 citations
Semantic Scholar
Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results from the Phase 1/2 BRUIN Study
Michael L. Wang, N. Shah, A. Alencar, J. Gerson +31 more
2021Blood13 citations Open access
Semantic Scholar
Ibrutinib Plus Rituximab and Venetoclax (IRV) Followed By Risk-Stratified Observation or Short Course R-Hypercvad/MTX in Young Patients with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-2 Clinical Trial
Michael L. Wang, P. Jain, Hun Lee, Young-Ok Chi +18 more
2021Blood13 citations Open access
Semantic Scholar
Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Efficacy and Safety Results from a Phase 2 Study
Michael L. Wang, S. Rule, P. Zinzani, A. Goy +21 more
2020Blood12 citations
Semantic Scholar
CAR-T and other adoptive cell therapies for B cell malignancies
P. Lu, H. Hill, L. Navsaria, Michael L. Wang
2021Journal of the National Cancer Center11 citations Open access
Semantic Scholar
Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K β/δ in relapsed refractory B cell lymphoma
L. Nastoupil, S. Neelapu, R. Davis, F. Samaniego +14 more
2021Leukemia and Lymphoma11 citations
Semantic Scholar
Outcomes with KTE-X19 in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in ZUMA-2 who had progression of disease within 24 months of diagnosis (POD24).
Michael L. Wang, J. Muñoz, A. Goy, F. Locke +16 more
20219 citations
Semantic Scholar
Phase 1 Dose Escalation and Cohort Expansion Study of the Anti-ROR1 Antibody-Drug Conjugate Zilovertamab Vedotin (MK-2140) for the Treatment of Non-Hodgkin Lymphoma
Michael L. Wang, M. Mei, P. Barr, J. Barrientos +10 more
2021Blood9 citations Open access
Semantic Scholar
Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant
Hua-Jay J. Cherng, Guo-Fan Xu, Lei Feng, R. Steiner +21 more
2022British Journal of Haematology8 citations
Semantic Scholar
Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma
Ravi K. Goyal, P. Jain, S. Nagar, H. Le +5 more
2021Leukemia and Lymphoma7 citations
Semantic Scholar
Safety and Efficacy of Acalabrutinib Plus Venetoclax and Rituximab in Patients with Treatment-Naïve (TN) Mantle Cell Lymphoma (MCL)
Michael L. Wang, T. Robak, K. Maddocks, T. Phillips +6 more
2021Blood7 citations Open access
Semantic Scholar
BRUIN MCL-321: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated, BTK Inhibitor Naïve Mantle Cell Lymphoma (Trial in Progress)
T. Eyre, N. Shah, S. le Gouill, M. Dreyling +12 more
2021Blood7 citations Open access
Semantic Scholar
KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL): Results of the Phase 2 ZUMA-2 Study
Michael L. Wang, J. Muñoz, A. Goy, F. Locke +16 more
20207 citations Open access
Semantic Scholar
Computer-aided detection of mantle cell lymphoma on 18F-FDG PET/CT using a deep learning convolutional neural network.
Zi-Jian Zhou, P. Jain, Yang Lu, H. Macapinlac +5 more
2021American Journal of Nuclear Medicine and Molecular Imaging6 citations
Semantic Scholar
Epstein Barr virus–positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo
Xiaoshan Zhang, Ran Zhang, C. Ren, Yi Xu +20 more
2021Blood Advances6 citations Open access
Semantic Scholar
Pharmacological Profile and Clinical Outcomes of KTE-X19 By Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Exposure or Mantle Cell Lymphoma (MCL) Morphology in Patients With Relapsed/Refractory (R/R) MCL in the ZUMA-2 Trial
Michael L. Wang, J. Rossi, J. Muñoz, A. Goy +12 more
20206 citations Open access
Semantic Scholar
Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study
Hun Lee, M. Choi, T. Siddiqi, W. Wierda +16 more
20205 citations
Semantic Scholar
Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX in Patients (age ≤ 65 years) with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-1 Clinical Trial
Michael L. Wang, P. Jain, Yi-Xin Yao, Yang Liu +26 more
20205 citations Open access
Semantic Scholar
Combination of Ibrutinib with Rituximab (IR) in Previously Untreated Older Patients with Mantle Cell Lymphoma (MCL) - a Phase II Clinical Trial
P. Jain, Yi-Xin Yao, Shuang-Tao Zhao, Yang Liu +31 more
20205 citations Open access
Semantic Scholar
Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL
P. Strati, M. Ahmed, L. Nastoupil, Lei Feng +17 more
2020Leukemia and Lymphoma5 citations
Semantic Scholar
Pirtobrutinib Overcomes Ibrutinib and Venetoclax Resistance in Mantle Cell Lymphoma
Yang Liu, Chang-Ying Jiang, F. Yan, J. McIntosh +7 more
2021Blood4 citations Open access
Semantic Scholar
Bispecific CD19-CD20 and CD19-CD22 CAR-T Cells with Glycogen Synthase Kinase (GSK)-3β Inhibitor TWS119 Treatment Have Superior Therapeutic Effects on Mantle Cell Lymphoma
Jing-Ling Jin, Yi-Jing Li, Yang Liu, Alexa A. Jordan +5 more
2021Blood4 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

P. Jain×15
Invite
P. Jain — researcher profile on SciRah
Saira S. Ahmed×12
Invite
Saira S. Ahmed — researcher profile on SciRah
L. Nastoupil×12
Invite
L. Nastoupil — researcher profile on SciRah
R. Nair×11
Invite
R. Nair — researcher profile on SciRah

×11

Invite

Hun Lee — researcher profile on SciRah

F. Samaniego×10

Invite

F. Samaniego — researcher profile on SciRah

Invite

R. Steiner — researcher profile on SciRah

Invite

C. Flowers — researcher profile on SciRah

Invite

J. Westin — researcher profile on SciRah

Invite

S. Neelapu — researcher profile on SciRah

Invite

P. Strati — researcher profile on SciRah

Invite

Lei Feng — researcher profile on SciRah